Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson's Disease with Dementia Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blarcamesine (Primary)
Indications Dementia; Parkinson's disease
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Anavex Life Sciences

Most Recent Events

09 May 2023 Interim results published in an Anavex Life Sciences Media Release.
04 Aug 2022 Results of Whole blood transcriptomics analysis identifying treatment impact on compensatory pathways by restoring key neurodegenerative pathways functionality, including Alzheimers disease pathway, presented at the Alzheimer's Association International Conference 2022
31 Jul 2022 Results presented in the Anavex Life Sciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com